Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: A retrospective cohort study Epidemiology and Health Outcomes

Wendy L St Peter, Akeem A. Yusuf, Thy Do, Kimberly A. Lowe, Jiannong Liu, Kimberly M. Nieman, Brian D. Bradbury, Allan J. Collins

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels after first cinacalcet prescription could serve as a surrogate marker for improvements in longer-term clinical outcomes. Methods: United States Renal Data System data were linked with data from a large dialysis organization. We created a point prevalent cohort of adult hemodialysis patients with Medicare as primary payer who initiated cinacalcet November 1, 2004-February 1, 2007, and were on cinacalcet for∈

Original languageEnglish (US)
Article number41
JournalBMC Nephrology
Volume16
Issue number1
DOIs
StatePublished - Mar 31 2015

Keywords

  • Cinacalcet
  • Hemodialysis
  • Parathyroid hormone
  • Secondary hyperparathyroidism

Fingerprint Dive into the research topics of 'Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: A retrospective cohort study Epidemiology and Health Outcomes'. Together they form a unique fingerprint.

  • Cite this